Qualitative Methods in Early-Phase Drug Trials: Broadening the Scope of Data and Methods From an RCT of N-Acetylcysteine in Schizophrenia
Michael Berk, Ahmed Munib, Olivia Dean, Gin S Malhi, Kristy Kohlmann, Ian Schapkaitz, Sue Jeavons, Fiona Katz, Murray Anderson-Hunt, Philippe Conus, Barbara Hanna, Renee Otmar, Felicity Ng, David L Copolov, Ashley I Bush
Journal of Clinical Psychiatry | PHYSICIANS POSTGRADUATE PRESS | Published : 2011
Dr Berk has received grant/research support from the Stanley Medical Research Foundation, MBF, National Health and Medical Research Council, Beyond Blue, Geelong Medical Research Foundation, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, Servier, and AstraZeneca; has been a paid consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Servier, and Pfizer; and has been a paid speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Organon, Pfizer, sanofi synthelabo, Servier, Solvay, and Wyeth. Dr Bush is a shareholder and consultant for Prana Biotechnology Ltd and a shareholder in Cogstate Ltd. Drs Munib, Dean, Mali, Schapkaitz, Jeavons, Anderson-Hunt, Conus, Hanna, Ng, and Copolov and Mss Kohlmann, Katz, and Otmar have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.The research team would like to thank the Stanley Medical Research Institute for providing funding for this trial.